The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study
- 30 November 1996
- Vol. 19 (5), 527-533
- https://doi.org/10.1016/s8756-3282(96)00229-3
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Serum Alkaline Phosphatase During Hormone Treatment in Early Postmenopausal WomenActa Medica Scandinavica, 2009
- Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessmentJournal of Clinical Endocrinology & Metabolism, 1995
- Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone diseaseJournal of Clinical Endocrinology & Metabolism, 1994
- Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosisAmerican Journal Of Medicine, 1993
- Can we improve compliance with long-term HRT?Maturitas, 1992
- Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancyBone, 1991
- Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responsesClinical Endocrinology, 1991
- Long-Term Estrogen Replacement Therapy Prevents Bone Loss and FracturesAnnals of Internal Medicine, 1985
- Prevention of early postmenopausal bone loss: controlled 2‐year study in 315 normal femalesEuropean Journal of Clinical Investigation, 1980
- Recommended Methods for the Determination of Four Enzymes in BloodScandinavian Journal of Clinical and Laboratory Investigation, 1974